Researchers predict a steady increase in fatty liver disease in the U.S. population, but there's not a lot of treatment ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A small clinical trial in China suggests that a low-dose vitamin E supplement could improve liver tissues and scarring for ...

Over the last year, 89bio’s stock has been somewhat volatile. Shares climbed past $10 earlier this year, but dropped under $6 ...

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic ...

Data from a meta-analysis of 8 observational studies accounting for more than 26 million people across the globe were ...

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Multiple treatment modalities ...

Unlike liver disease linked to alcohol abuse, MASLD is driven largely by metabolic imbalances, poor diet and sedentary ...

89bio, Inc. is a clinical-stage biotech focused on liver and cardio-metabolic diseases, with its lead drug candidate ...

The addition of multiparametric MRI to standard of care was cost-effective and enhanced diagnosis rates among patients with ...

April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage ...